Harm reduction may become a resting place for addiction treatment. Dr. Neff shares his insight to pursue deeper and more comprehensive healing whenever possible.
As discussed in last month’s column psychiatry is rife with shibboleths—catchphrases that function as stock heuristics. They simplify complex clinical realities and can make us feel articulate and decisive, both to ourselves and to others. Few such phrases have captured the imagination of the addiction treatment community more thoroughly than harm reduction. Much ballyhooed, the concept can support thoughtful, pragmatic clinical decision-making—but it can also be used to justify paradigms that are careless, incomplete, or insufficient.
A careful examination of what harm reduction should mean, and what it decidedly should not mean, is therefore overdue. Psychiatrists have an obligation to think beyond the slogans they inherit and repeat. Anything less risks abandoning the humanistic, patient-centered care we are duty-bound to provide. When we understand harm reduction clearly, we are better equipped to use it as intended: as a tool to heal our patients.
At its best, harm reduction acknowledges that at any given stage of illness, a patient may not be ready—or able—to engage in every possible intervention. Earlier models of addiction treatment often emphasized an all-or-nothing approach, frequently accompanied by moral judgment. Harm reduction, by contrast, urges clinicians to actively pursue the treatments a patient is willing to accept, rather than penalizing them for failing to meet every recommendation.
Here, the chronic disease model offers a useful analogy. No reasonable physician would withhold insulin from a patient with a hemoglobin A1c of 12 simply because they have been unable to implement meaningful lifestyle changes. Similarly, no competent clinician should deny medication-assisted treatment or other evidence-based interventions to patients who are not yet able to meaningfully alter their substance use behaviors. By embracing harm reduction, the field has expanded access to care for countless individuals who would historically have been excluded.
However, harm reduction is too often misapplied as a justification for clinical inertia. Some clinicians—and the administrators who support them—invoke harm reduction primarily as a means of lowering the threshold for entry into treatment. Once patients are enrolled, the same framework may be used indefinitely to justify ongoing care without reassessment or escalation. In this formulation, harm reduction becomes not a starting point, but a resting place.
Yet the goal of treatment cannot be merely to reduce harm to some arbitrary level and then congratulate ourselves for having done so. Our responsibility is not simply to lessen damage, but to pursue deeper and more comprehensive healing whenever possible. Returning again to diabetes: no clinician would initiate insulin therapy and then suggest that lifestyle modification no longer matters.
Patients deserve care that is both compassionate and aspirational. Harm reduction provides an essential entry point into treatment, but it should rarely serve as the endpoint. Only when we continue to communicate our belief that patients are capable of further growth and recovery can we be confident that we are fully honoring our commitment to their care.